ArticleScientific reports2022

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors.

Markus Perbandt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.